search
Back to results

Improve the Patients' Recovery With Family- Caregivers to End Delirium (iPREPARED)

Primary Purpose

Delirium

Status
Suspended
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
iPREPARED
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Delirium focused on measuring Aged 60 years old or older, Hospitalized with a risk of confusion, At risk of falling, At risk of vision or hearing impaired

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Patient Inclusion Criteria:

  • 60 years of age or older
  • Have 1 risk factor for delirium (pre-existing cognitive impairment, vision/hearing impairment, identified as high risk for falls, illness rated as severe)
  • Estimated length of stay of 24 hours or more in hospital
  • Have an informal caregiver (18 years of age or older, family member or friend) willing to participate

Patient Exclusion Criteria:

  • Patient lacks capacity to consent
  • Unable to communicate or participate in study due to language barriers or sensory deficits
  • Prisoners
  • Documented history of dementia in the medical record
  • Patient admitted to hospice service or actively dying
  • Delirium present upon admission to hospital
  • COVID-19 positive test

Caregiver Inclusion Criteria:

  • 18 years of age or older
  • Family member, friend, or neighbor of the patient willing to participate in the study and support the patient during the study period (support can be in-person or virtual)

Caregiver Exclusion Criteria:

- Unable or unwilling to participate due to language barriers, availability, or other communication barriers

Sites / Locations

  • Mayo Clinic in Rochester

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

IPREPARED Hospital Recovery Club

Standard Hospital Care Group

Arm Description

Participants and their recovery partners (informal caregivers) will use the iPREPARED mobile health technology. They will watch a short video to prepare them for their hospital stay and asked to use the provided resources and tools to maintain their brain health during their hospital stay.

Participants will receive standard protocolized care procedures.

Outcomes

Primary Outcome Measures

Feasibility of study recruitment to intervention study
Total number of patient-caregiver dyads enrolled in the study
Usability and acceptability of digital technology
Measured using the System Usability Scale and the treatment acceptability preference questionnaire which measure the participants self-reported usability and acceptability of the iPREPARED intervention.
Delirium incidence
The incidence of delirium will be assessed upon enrollment then twice daily on days 1-4 of the study, and upon hospital discharge using the 3DCAM. Effect sizes between groups will be generated for future larger studies.

Secondary Outcome Measures

Delirium-related distress
The NCCN distress thermometer will be used twice daily to assess the level of self-reported distress associated with the signs and symptoms of delirium.
Resiliency
Measured using the brief resilience scale that assesses the participants ability to recover from stressful events through 6-item questionnaire asking participants to response to questions on a scale of strongly disagree, disagree, neutral, agree, or strongly agree.
General Self-Rated Health Status
Measured using the self-reported general self-rated health status (GSRH) asking participants to rate their general health as good, rather good, poor, or very poor.
Delirium Severity
Delirium severity will be assessed using the Delirium Rating Scale - R- 98 (DRS-R-98). This will be assessed upon enrollment, twice daily on hospital days 1-4, and upon discharge.
Acute Stress associated with the hospitalization
The Intensive Care Psychological Assessment Tool (IPAT) will be administered with concurrent delirium incidence and severity measurement.47 This is a 10-item scale that evaluates how a patient has been feeling since their admission. These answers will inform the delirium assessments.
Biomarkers
Plasma and serum biomarker differences between groups and between delirium/non-delirium cohort
Discharge disposition
Place (home, rehabilitation facility, long term care facility) that patient was discharged from the hospital to for continued care.
30-day readmission rates
Rate of patients that were re-admitted to the hospital following the index hospitalization
Length of hospital stay
Number of days admitted to hospital

Full Information

First Posted
October 8, 2021
Last Updated
December 29, 2022
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT05118867
Brief Title
Improve the Patients' Recovery With Family- Caregivers to End Delirium
Acronym
iPREPARED
Official Title
Improve the Patients' Recovery by Engagement and Partnerships With Family- CaregiveRs to End Delirium (iPREPARED) - A Feasibility and Acceptability Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Suspended
Why Stopped
To update technology based on feedback from participants
Study Start Date
December 16, 2021 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This research is being done to find out if patients and caregivers who use the iPREPARED mobile health technology experience less delirium, a type of acute confusion, and if they do experience delirium, the delirium will be less severe and distressful. iPREPARED prepares patients and caregivers on what to expect during their hospital stay and provides instructions and resources on how to use non-pharmacologic strategies like re-orientation, distraction techniques, and other activities to maintain their brain health during their hospital stay.
Detailed Description
The purpose of this pilot study is to assess the feasibility, acceptability, and preliminary efficacy of the iPREPARED mobile health technology to reduce delirium incidence in a two-group, pilot randomized- controlled clinical trial. In the context of this intervention, the caregiver is defined as a patient-identified family member or friend that can accompany the patient in their hospital journey. Aim 1: Determine the feasibility, acceptability, and usability of the iPREPARED intervention for use by older hospitalized adults (>60yo) and their caregivers (patient-caregiver dyad). Aim 2: To estimate the effect size needed to reduce the incidence of delirium in participants using the iPREPARED intervention. Aim 3: Identify patient-caregiver reported strategies to improve the usability of the iPREPARED intervention. Secondary Outcomes: Association between delirium incidence and self-rated health status (GSRH). Association between delirium incidence, severity, and delirium-related distress (NCCN Distress thermometer) and resiliency (BRS resiliency scale). Acute stress measured by the IPAT will be compared across the two groups. Acute stress measured by the Intensive Care Psychological Assessment Tool (IPAT) will be less in the intervention group. Delirium-related distress will be analyzed across the two groups. Delirium-related distress measured by the NCCN Distress Thermometer will be less in the intervention group. Plasma and serum biomarker differences between groups and between delirium/non- delirium cohort. Clinical outcomes including adverse hospital events (falls, nosocomial infections, aspirations), length of hospital stay, discharge disposition, mortality and 30-day readmission rates will be collected and examined between groups: Nosocomial infection is defined as a diagnosis not present on admission and occurred after 48 hours of hospital admission and includes UTI, Pneumonia, Decub ulcers, Cellulitis, CAUTI's and CLABSI's

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
Keywords
Aged 60 years old or older, Hospitalized with a risk of confusion, At risk of falling, At risk of vision or hearing impaired

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IPREPARED Hospital Recovery Club
Arm Type
Experimental
Arm Description
Participants and their recovery partners (informal caregivers) will use the iPREPARED mobile health technology. They will watch a short video to prepare them for their hospital stay and asked to use the provided resources and tools to maintain their brain health during their hospital stay.
Arm Title
Standard Hospital Care Group
Arm Type
No Intervention
Arm Description
Participants will receive standard protocolized care procedures.
Intervention Type
Behavioral
Intervention Name(s)
iPREPARED
Intervention Description
iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
Primary Outcome Measure Information:
Title
Feasibility of study recruitment to intervention study
Description
Total number of patient-caregiver dyads enrolled in the study
Time Frame
Number approached for study that were eligible and number consented into study over 2-year study.
Title
Usability and acceptability of digital technology
Description
Measured using the System Usability Scale and the treatment acceptability preference questionnaire which measure the participants self-reported usability and acceptability of the iPREPARED intervention.
Time Frame
From enrollment through study completion, an average of 4 days
Title
Delirium incidence
Description
The incidence of delirium will be assessed upon enrollment then twice daily on days 1-4 of the study, and upon hospital discharge using the 3DCAM. Effect sizes between groups will be generated for future larger studies.
Time Frame
From enrollment through study completion, an average of 4 days
Secondary Outcome Measure Information:
Title
Delirium-related distress
Description
The NCCN distress thermometer will be used twice daily to assess the level of self-reported distress associated with the signs and symptoms of delirium.
Time Frame
From enrollment through study completion, an average of 4 days
Title
Resiliency
Description
Measured using the brief resilience scale that assesses the participants ability to recover from stressful events through 6-item questionnaire asking participants to response to questions on a scale of strongly disagree, disagree, neutral, agree, or strongly agree.
Time Frame
At enrollment into study
Title
General Self-Rated Health Status
Description
Measured using the self-reported general self-rated health status (GSRH) asking participants to rate their general health as good, rather good, poor, or very poor.
Time Frame
At enrollment into study
Title
Delirium Severity
Description
Delirium severity will be assessed using the Delirium Rating Scale - R- 98 (DRS-R-98). This will be assessed upon enrollment, twice daily on hospital days 1-4, and upon discharge.
Time Frame
From enrollment through study completion, an average of 4 days
Title
Acute Stress associated with the hospitalization
Description
The Intensive Care Psychological Assessment Tool (IPAT) will be administered with concurrent delirium incidence and severity measurement.47 This is a 10-item scale that evaluates how a patient has been feeling since their admission. These answers will inform the delirium assessments.
Time Frame
From enrollment through study completion, an average of 4 days
Title
Biomarkers
Description
Plasma and serum biomarker differences between groups and between delirium/non-delirium cohort
Time Frame
At enrollment and Day 4
Title
Discharge disposition
Description
Place (home, rehabilitation facility, long term care facility) that patient was discharged from the hospital to for continued care.
Time Frame
From enrollment through study completion, an average of 4 days
Title
30-day readmission rates
Description
Rate of patients that were re-admitted to the hospital following the index hospitalization
Time Frame
30-days after hospital discharge date
Title
Length of hospital stay
Description
Number of days admitted to hospital
Time Frame
From enrollment through study completion, an average of 4 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Patient Inclusion Criteria: 60 years of age or older Have 1 risk factor for delirium (pre-existing cognitive impairment, vision/hearing impairment, identified as high risk for falls, illness rated as severe) Estimated length of stay of 24 hours or more in hospital Have an informal caregiver (18 years of age or older, family member or friend) willing to participate Patient Exclusion Criteria: Patient lacks capacity to consent Unable to communicate or participate in study due to language barriers or sensory deficits Prisoners Documented history of dementia in the medical record Patient admitted to hospice service or actively dying Delirium present upon admission to hospital COVID-19 positive test Caregiver Inclusion Criteria: 18 years of age or older Family member, friend, or neighbor of the patient willing to participate in the study and support the patient during the study period (support can be in-person or virtual) Caregiver Exclusion Criteria: - Unable or unwilling to participate due to language barriers, availability, or other communication barriers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heidi Lindroth, PhD, RN
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be shared with the NIDUS network and for other interested investigators. Please contact study team.
IPD Sharing Time Frame
November 1 2021-December 31 2023
IPD Sharing Access Criteria
Email investigator
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Improve the Patients' Recovery With Family- Caregivers to End Delirium

We'll reach out to this number within 24 hrs